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Abstract
Background: The neural cell adhesion molecule L1 plays a crucial role in development and
plasticity of the nervous system. Neural cells thus require precise control of L1 expression.
Results: We identified a full binding site for nuclear factor I (NFI) transcription factors in the
regulatory region of the mouse L1 gene. Electrophoretic mobility shift assay (EMSA) showed
binding of nuclear factor I-A (NFI-A) to this site. Moreover, for a brain-specific isoform of NFI-A
(NFI-A bs), we confirmed the interaction in vivo using chromatin immunoprecipitation (ChIP).
Reporter gene assays showed that in neuroblastoma cells, overexpression of NFI-A bs repressed
L1 expression threefold.
Conclusion: Our findings suggest that NFI-A, in particular its brain-specific isoform, represses L1
gene expression, and might act as a second silencer of L1 in addition to the neural restrictive
silencer factor (NRSF).
Background
Neural adhesion molecules of the immunoglobulin
superfamily mediate cell-cell recognition by homo- or
heterophilic Ca2+-independent cell surface interactions
[1]. L1, a member of this family, promotes neurite out-
growth and fasciculation, and is involved in axonal path-
finding, neuronal migration, regeneration and synaptic
plasticity [1,2]. Targeted ablation of L1 in mice leads to
hydrocephalus, corpus callosum hypoplasia, and malfor-
mation of the corticospinal tract resembling mutations in
the human L1 gene that result in an X-linked recessive
neurological disorder called X-linked hydrocephalus,
MASA syndrome or spastic paraplegia type I (SPG1)
(reviewed by [1]). These observations in mice and man
point to a key role of L1 in development of the nervous
system.
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In the control region of the mouse L1  gene, a neural
restrictive silencer element (NRSE) was identified which is
responsible for the neuronal expression of L1 during
embryonic development and serves as a tissue-specific
silencer and enhancer in postnatal animals [3,4]. Moreo-
ver, the transcription factors Pax-6, Hoxa-1, and Barx2
bind to the murine L1 gene regulatory region, and Pax-6
activates mouse L1  gene expression [5,6]. More recent
studies have identified two additional activators of L1
transcription, LEF-1/TCF in human colorectal cancer cells
[7], and KLF7 in olfactory sensory neurons [8]. Nuclear
factor I-A (NFI-A), a member of the nuclear factor I (NFI)
family of site-specific transcription factors, is a good can-
didate for controlling L1 transcription, as it regulates the
expression of several neural proteins and thereby governs
development of the central nervous system in mice and
men (reviewed by [9,10]). In the present study, we tested
whether NFI-A binds to the murine L1 gene regulatory
region and influences L1 gene expression.
Methods
Plasmid constructs
The L1 reporter plasmid L1-11 [3], a kind gift from Dr. P.
Kallunki (H. Lundbeck A/S, Valby, Denmark), contains
2943 bp upstream of exon 1 of the mouse L1 gene, exon
1, intron 1, exon 2 with the luciferase cDNA inserted to
replace the L1 start codon by the luciferase start codon,
intron 2 including the neural restrictive silencer element,
exon 3, intron 3 and exon 4. The NFI-A expression plas-
mid pCHNFI-A has been described previously [11] and
expresses the hemagglutinin (HA) epitope-tagged [12]
murine ortholog of chicken NFI-A1.1 [13], which, in this
paper, is called "standard isoform" due to its widespread
expression in various tissues of adult mice [11]. To express
the brain-specific isoform of mouse NFI-A [14] in an HA
epitope-tagged form, pCHBNFI-A was used, which was
constructed analogously to pCHNFI-A. A plasmid which
expresses brain-specific NFI-A lacking most of the activa-
tion domain (pCHBNFI-Am) was created by digesting the
parental vector with BstXI and KpnI. 3' overhangs were
removed by incubation with Platinum Pfx DNA Polymer-
ase (Invitrogen, Karlsruhe, Germany) at 68°C for 15 min,
and the resulting blunt ends were ligated using the Rapid
DNA Ligation Kit (Roche, Mannheim, Germany). For
ChIP experiments, Myc-tagged expression constructs for
the standard and brain-specific NFI-A isoforms were made
by cutting out the HA tag with NotI and SfiI from pCHNFI-
A and pCHBNFI-A, respectively. Two oligonucleotides,
NFI-Myc 1 (GGCCGCTATGGAACAAAAACTCATCTCA-
GAAGAGGATCTGCAC) and NFI-Myc 2 (CAGATCCTCT-
TCTGAGATGAGTTTTTGTTCCATAGC) (Metabion,
Martinsried, Germany), which contain the coding
sequence of the Myc epitope combined with Kozak box,
start codon and the compatible nucleotide overhangs,
were annealed. The resulting double-stranded oligonucle-
otide was added to a 5-10 fold excess of the respective
NotI/SfiI-digested NFI-A expression vector, and ligated
using the Rapid DNA Ligation Kit.
The CMX expression plasmid coding for β-galactosidase
[15] was kindly provided by Dr. R. M. Evans (Salk Insti-
tute, La Jolla, CA, USA).
Cell culture
Mouse neuroblastoma cells (N2A) were maintained in
Dulbecco's modified Eagle's medium (DMEM) contain-
ing 10% fetal calf serum, 1 mM sodium pyruvate, 2 mM
L-glutamine, and antibiotics (100 units/ml penicillin and
100 μg/ml streptomycin). For reporter gene assays, N2A
cells were grown in Opti-MEM without phenol red (Invit-
rogen, Karlsruhe. Germany) supplemented with 5% fetal
calf serum, 200 units/ml of penicillin G, and 200 μg/ml
streptomycin. Chinese hamster ovary cells (CHO) were
grown in Glasgow minimum essential medium (GMEM),
which contained 10% fetal calf serum, 4 mM L-glutamine,
and antibiotics (100 units/ml penicillin and 100 μg/ml
streptomycin). All cell types were grown at 37°C under a
5% CO2 atmosphere.
Electrophoretic mobility shift assays (EMSAs)
For EMSAs, HA-NFI-A constructs were expressed in CHO
cells. Cells were plated onto 90-mm dishes in CHO cul-
ture medium. After reaching confluence, cells were
washed once with CHO culture medium without serum
and antibiotics. Transfections were performed with Lipo-
fectamine (Invitrogen) according to the manufacturer's
instructions. Per dish, 13 μg of the respective plasmid
were transfected with 26 μl Lipofectamine and 39 μl Plus
Reagent (Invitrogen). Three h later, the transfection reac-
tion was stopped by addition of 6.5 ml CHO culture
medium. 24 h after transfection, cell monolayers were
washed once with PBS and harvested by scraping into PBS
supplemented with Complete protease inhibitor (Roche).
Cells were pelleted by spinning for 10 min at 4°C (300 ×
g), the supernatant was removed and the pellet resus-
pended in low salt lysis buffer (20 mM HEPES pH 7.8, 100
mM NaCl, 5 mM DTT, 1 × Complete protease inhibitor
(Roche)). The cell suspension underwent three freeze-
thaw cycles in dry ice/ethanol. Cell debris were removed
by centrifugation (15 min, 4°C, 15000 × g), and the
supernatant was used for DNA binding analysis. The elec-
trophoretic mobility shift experiments were essentially
performed as described [16]. In brief, single-stranded oli-
gonucleotides were purchased (Metabion) and annealed,
yielding double-stranded oligonucleotides with 5' over-
hangs. Double-stranded oligonucleotides were labeled
with  α-32P-dCTP using Klenow polymerase (Roche).
Binding reactions were performed in a total volume of 10
μl consisting of 20 mM HEPES pH 7.8, 100 mM NaCl, 2
mM MgCl2, 7 mM DTT, 0.5 μg Cot-1 DNA, and 3 μl of cellBMC Molecular Biology 2009, 10:107 http://www.biomedcentral.com/1471-2199/10/107
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lysate. Complete protease inhibitor was added according
to the manufacturer's specifications (Roche). Binding
reactions were incubated for 20 min followed by the addi-
tion of 2 μl of the labeled oligonucleotides, and incubated
further for 20 min at room temperature. For the super-
shift, 1 μl of undiluted anti-HA (clone 12CA5, Roche) was
added before loading, and incubated for another 20 min.
In the case of competition experiments, radioactively
labeled oligonucleotides were mixed with a 5-100 fold
molar excess of the respective unlabeled oligonucleotides
before being added to the binding reaction. Complexes
were resolved by nondenaturing PAGE, and dried gels
were exposed to BioMax MR film (Kodak, Stuttgart, Ger-
many).
Oligonucleotides used were as follows: L, 5'-gctatTT-
GGCTTGGTGCCAAgcatc-3'; Lc, 5'-gctatTTCGCTTGGT-
GCCAAgcatc-3'; N, 5'-aggtCTGGCTTTGGGCCAAgagccgc-
3'; Nc, aggtCTCGCTTTGGGCCAAgagccgc-3'; SIS, 5'-
agcttaccagaaggtcaaggtcaaatgaagctagct-3' Sequences corre-
sponding to the NFI binding site are capitalized; muta-
tions in the negative control oligonucleotides are shown
in boldface. The sequence of one strand is shown after the
fill-in reaction.
Western Blot
In order to check HA-NFI-A expression by Western Blot,
transfection of CHO cells was performed as described for
EMSAs. However, 6-well plates were used, with DNA
amounts and volumes of media and reagents adjusted
accordingly. 24 h after transfection, cells were lysed by
incubating in Ripa buffer (50 mM Tris pH 7.4, 150 mM
NaCl, 1 mM EDTA, 0.5% (w/v) NP-40, 1 × Complete pro-
tease inhibitor (Roche)) for 1 h at 4°C. Cell debris were
removed by centrifugation (15000 × g, 4°C, 10 min). The
supernatant was mixed with sample buffer and boiled for
5 min. Proteins were separated by SDS-PAGE, transferred
to a nitrocellulose membrane, and immunologically
detected as described (Kalus et al. 2003). Anti-HA (from
mouse, clone 12CA5, Roche) was used as primary anti-
body (1:400 in 4% milk powder in Tris-HCl-buffered
saline (pH 7.3)). Horseradish peroxidase-conjugated goat
anti-mouse secondary antibody (Dianova, Hamburg, Ger-
many) was applied at a 1:10,000 dilution in 4% milk
powder in Tris-HCl-buffered saline (pH 7.3). Detection of
Myc-NFI-A st and Myc-NFI-A bs expression in N2A cells
was performed following the same protocol, using anti-
Myc (from mouse, clone 9E10, Santa Cruz, Heidelberg,
Germany) as a primary antibody. Transfection of the
respective plasmids was performed as described under
"Chromatin immunoprecipitation assay". However, 6-
well plates were used, with DNA amounts and volumes of
media and reagents adjusted accordingly. To check for the
amount of protein loaded per lane, an anti-GAPDH anti-
body was applied (anti-GAPDH from rabbit, Cell Signal-
ling, mAb 14C10, 1:1000; followed by anti-rabbit-IgG-
HRP, 1:20,000).
Chromatin immunoprecipitation assay (ChIP)
Myc-tagged NFI-A expression for ChIPs was carried out in
N2A cells, cultivated on 90-mm dishes until confluency.
13 μg of the respective plasmid were transfected with 26
μl Lipofectamine and 39 μl Plus Reagent (Invitrogen) per
dish according to the manufacturer's instructions. 48 h
later, ChIP analysis was essentially performed as described
[17]. For reduction of non-specific background, 0.5 μg
anti-HA was applied per precipitation. Specific precipita-
tion was achieved using anti-Myc. DNA fragments were
purified with the MinElute PCR purification kit (Qiagen,
Hilden, Germany). Subsequent PCR was carried out with
the primers ChIP fw, GGAGTTCAAATGCCTTAACATGA,
and ChIP rev, CTGGATGCCCTCAATAAATTCAT. For neg-
ative control amplifications of remote gene loci, the fol-
lowing primers were used: Chst11 fw,
TGGAGACAGCCCTCCATAGATGT; Chst11 rev, GAT-
GGCAGTGTTGGATAGCTCCA; Chst8 fw, GTAAACGACT-
TCTCCTACCGCA; Chst8 rev, GTATTGTCACAGGG
ACGATGTCCA. Amplification comprised 25 cycles, with
the annealing temperature set to 55°C. As a positive con-
trol, genomic DNA from C57BL/6J mouse tail cuts was
used, which was prepared according to the following pro-
tocol: tail cuts were incubated over night at 55°C in 100
μl lysis buffer (0.1 mg/ml proteinase K (Sigma,
Taufkirchen, Germany); 50 mM Tris pH 8.0; 50 mM KCl;
2.5 mM EDTA; 0.45% NP-40 and 0.45% Tween-20). The
next day, tissue debris were spun down, and the whole
supernatant was extracted with an equal volume of PCI
(phenol-chloroform-isoamyl alcohol, Biochrom, Berlin,
Germany). DNA was precipitated with 2.5 volumes of eth-
anol and 0.1 volumes of 8 M LiCl. The pellet was washed
with 70% ethanol and, after drying, resuspended in 50-
100 μl 1 mM Tris pH 8.0.
Luciferase-based reporter gene assays
For transient transfections, 1 × 104 mouse neuroblastoma
(N2A) cells were seeded in 96-well tissue culture plates
(Greiner, Frickenhausen, Germany) and transfected the
next day with 2.5 μl Lipofectamine 2000 (Invitrogen) per
microgram of DNA. 80 ng reporter plasmid (L1-11), 60 ng
of the effector plasmids (pCHBNFI-A or pCHBNFI-Am) or
control CMX plasmid coding for β-galactosidase were
applied per well. EGFP fluorescence generated by cotrans-
fection of 60 ng pEGFP-C3 (Clontech, Heidelberg, Ger-
many) was determined after 48 hours with a Wallac 1420
Multilabel Counter (PerkinElmer, Wiesbaden, Germany).
Luciferase activity was measured with the Bright-Glo Luci-
ferase Assay System according to the manufacturer's
instructions (Promega, Mannheim, Germany). Light
emission was normalized to the level of EGFP fluores-
cence activity from the EGFP control plasmid. Transfec-BMC Molecular Biology 2009, 10:107 http://www.biomedcentral.com/1471-2199/10/107
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tions were generally performed in septuplicate. Average
relative luciferase light units and standard deviations were
calculated using the Prism-4 program (GraphPad Soft-
ware, La Jolla, CA, USA).
Results
Identification of a full NFI binding site in the first intron of 
the mouse L1 gene
To ask whether NFI-A binds to the murine L1 gene regula-
tory region, we analyzed the nucleotide sequence of this
region [3,5,6] for NFI binding sites, using the Lasergene
(DNASTAR Inc., Madison, WI) software suite. We identi-
fied the sequence TTGGCTTGGTGCCAA, which fully
matches the NFI consensus motif, TTGGC(N)5GCCAA
[9], in intron 1, located 1341 bp upstream of the transla-
tion start codon in the second exon (Fig. 1). The same part
of the mouse L1 gene regulatory region also contains a
previously identified DNA element recognized by Pax-6
and by additional homeodomain proteins [6] (see Fig.
1B). In addition to the full binding site, we found eight
half binding sites for NFI proteins located within the 2400
bp immediately upstream of the full site (not shown).
NFI-A binds to the regulatory region of the mouse L1 gene 
in vitro
To assess binding of NFI-A to the full NFI recognition
motif in the L1 gene regulatory region in vitro, electro-
phoretic mobility shift assays (EMSAs) were performed,
using both the ubiquitous "standard" isoform of NFI-A
(NFI-A st) and a brain-specific isoform (NFI-A bs) [14].
Their unique N-termini of 32 (NFI-A bs) and 9 amino
acids (NFI-A st) are generated by alternative splicing [9]
The regulatory region of the mouse L1 gene contains a full NFI binding site Figure 1
The regulatory region of the mouse L1 gene contains a full NFI binding site. A, 15-nucleotide sequence (boldface) 
fully matching the NFI consensus binding motif [9]. Numbering with respect to the first nucleotide of exon 1 according to the 
mouse L1 gene nucleotide sequence deposited in GenBank (accession number NC_000086.6); sequences corresponding to the 
primers for ChIP analysis are underlined. B, The first four exons of the mouse L1 gene are indicated by boxes labeled E1-E4. 
Arrows: transcription initiation sites; ATG: translation start; filled circle: full NFI binding site; triangle: homeodomain and Pax pro-
tein binding site (HPD).BMC Molecular Biology 2009, 10:107 http://www.biomedcentral.com/1471-2199/10/107
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(Fig. 2A). Both HA-tagged isoforms were expressed in
CHO cells (Fig. 2B). Cell extracts were incubated with oli-
gonucleotides containing either the newly identified full
binding site in the mouse L1 gene (L), or an idealized NFI
binding site (N, [18]) (Fig. 3). To control for binding spe-
cificity, a G→C point mutation eliminating an essential
GN7 contact for NFI was introduced into both oligonucle-
otides, yielding Lc and Nc, respectively (Fig. 3). Both NFI-
A st and NFI-A bs expression caused a significant shift of
the L and N oligonucleotides (Fig. 3). Neither the Lc nor
the Nc oligonucleotide were shifted, indicating that the
guanosine in position 3 of the motif is critical for NFI-A
binding and that the complex is formed by sequence-spe-
cific interaction of NF1-A with both elements. Moreover,
no gel shift was observed for the unrelated SIS oligonucle-
otide (C) [16], which does not contain an NFI recognition
motif. Extracts without forced NFI-A expression ("CMV",
Fig. 3, label B) gave rise to faster mobility complexes.
Expression of HA-tagged NFI-A isoforms in CHO cells Figure 2
Expression of HA-tagged NFI-A isoforms in CHO 
cells. A, Schematic drawing of the brain-specific isoform 
("NFI-A bs") and the ubiquitous "standard" isoform ("NFI-A 
st") of mouse NFI-A. The isoform-specific N-termini (open 
rectangles) are encoded by exons 1a and 1b, respectively, and 
result from alternative splicing. Amino acid sequences 
encoded by these exons are given above and below. The 
major part of the protein (filled rectangles; not drawn to scale) 
is identical in both isoforms. Total length: 532 amino acids 
(NFI-A bs); 509 amino acids (NFI-A st). B, CHO cells were 
transfected with 2 μg of NFI-A cDNA expression vectors. 
Lane 1, pCHNFI-A ("standard" isoform); lane 2, pCHBNFI-A 
(brain-specific isoform); lane 3, mock transfected. Whole cell 
extracts were analyzed on an 8% SDS-PAGE gel, transferred 
to nitrocellulose membrane, and probed with anti-HA anti-
body. Filled arrows indicate bands which correspond to the 
respective HA-tagged NFI-A polypeptides, the open arrow 
shows a nonspecific band.
NFI-A binds to its full binding site in the mouse L1 gene in  vitro Figure 3
NFI-A binds to its full binding site in the mouse L1 
gene in vitro. 32P-labeled oligonucleotides used for EMSA: L: 
full NFI binding site in mouse L1 gene with flanking 
sequences; Lc: point-mutated variant of L; N: idealized NFI 
binding site with flanking sequences [18]; Nc: point-mutated 
variant of N; C: oligonucleotide without NFI recognition 
motif (SIS oligonucleotide). NFI binding site sequences are 
capitalized, point mutations are shown in boldface. The 
sequence of one strand is shown after the fill-in reaction. Oli-
gonucleotides were incubated with extracts from CHO cells 
expressing NFI-A bs or NFI-A st, or from mock-transfected 
cells (CMV). Only the upper and lower parts of the autoradi-
ogram are shown, the middle section, which did not exhibit 
any signals, was cut out for reasons of space. Arrows A: HA-
NFI-A-DNA complexes; arrow B: complexes of endogenous 
NFI and DNA; arrows C and D: free oligonucleotide DNA. 
Note that that the free SIS oligonucleotide migrates slightly 
slower (arrow C) than the other free oligonucleotides (arrow 
D) due to its higher molecular weight.BMC Molecular Biology 2009, 10:107 http://www.biomedcentral.com/1471-2199/10/107
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These complexes most likely represent endogenous NFI
isoforms as indicated by the lack of binding to the mutant
Lc, Nc and C oligos. The heterogeneity of these endog-
enous complexes and their reduction in the transfected
samples is likely due to the known alternative splicing of
NFI proteins and the ability of NFI proteins to form both
homo- and hetero-dimers in vivo, respectively. Specific
binding was confirmed with an anti-HA supershift exper-
iment (Fig. 4A).
In competition experiments, the L oligonucleotide was
more effective than the N oligonucleotide (Fig. 4B), impli-
cating a higher affinity of NFI-A to the site in the L1 gene
as compared to the idealized consensus site. The point-
mutated oligonucleotides Lc and Nc were unable to com-
pete with the intact binding motifs. We conclude that, in
vitro, NFI-A binds to its recognition site in the first intron
of the mouse L1 gene, and that this interaction is tight and
specific.
The brain-specific isoform of NFI-A binds to the regulatory 
region of the mouse L1 gene in vivo
To ask whether the interaction between NFI-A and its
binding motif in the mouse L1 gene regulatory region is
seen in vivo, we performed a chromatin immunoprecipita-
tion (ChIP) analysis. Mouse neuroblastoma (N2A) cells,
which express endogenous L1 [19], were transfected with
Myc-tagged NFI-A bs or Myc-tagged NFI-A st, respectively.
Precipitation was carried out with an anti-Myc antibody,
and PCR primers were chosen which specifically amplify
the region of the L1 gene flanking the NFI full binding site
(Fig. 1A). Fig. 5A (upper panel, L1) shows the outcome of
a representative experiment: whereas binding of the brain-
specific NFI-A isoform (NFI-A bs) to the L1 regulatory
region could be confirmed, no signal was obtained for the
ubiquitous isoform (NFI-A st). The same result was
observed in two further ChIP assays, and only in one
experiment, weak binding of NFI-A st was detected. Only
weak PCR signals were observed for mock-transfected
cells. As an additional negative control, segments of the
mouse Chst8 and Chst11 genes were amplified by PCR. No
signals were observed when ChIP precipitates were used
as a template (Fig. 5A, middle panel and lower panel),
confirming the specificity of NFI-A bs binding to the
mouse L1 gene. Western blot analysis revealed the pres-
ence of comparable amounts of both NFI-A isoforms in
transfected N2A cells (Fig. 5B). Thus, the brain-specific
isoform of NFI-A directly interacts with the endogenous
L1 gene regulatory region in a neuronal cell line.
NFI-A represses activity of the L1 gene in mouse 
neuroblastoma cells
For a functional analysis, the effect of forced NFI-A bs
expression on the activity of a previously described L1-
luciferase reporter construct, L1-11 [3], was determined in
N2A cells. The brain-specific isoform of NFI-A was chosen
because it reproducibly bound to the endogenous L1 reg-
ulatory region (Fig. 5A), whereas in vivo binding of the
ubiquitous NFI-A isoform appeared to be weaker. NFI-A
bs reduced L1 gene activity to less than one-third of con-
trol values (Fig. 6, second column from the right side).
Repression was concentration-dependent, suggesting a
specific effect (Fig. 6). Moreover, we investigated a
mutated form of NFI-A bs (NFI-A bs del), which lacked
the entire activation/repression domain. NFI-A bs del
should therefore be able to bind to DNA, but exhibit a
severely reduced ability to activate or repress target genes
[9]. In line with these expectations, expression of the trun-
cated NFI-A bs led to only a slight reduction of L1 tran-
scription (Fig. 6, rightmost column). Summarizing, our
data show a repressive influence of NFI-A bs on L1 gene
expression, which can be reverted by impairing NFI-A's
trans-regulatory abilities.
Discussion
The cell adhesion molecule L1 plays a crucial role in mam-
malian nervous system development, but regulation of its
expression at the transcriptional level is only partly under-
stood. Here, using EMSA and antibody supershift experi-
ments, we showed that the site-specific transcription
factor NFI-A specifically interacts with a full NFI recogni-
tion site in the first intron of the murine L1 gene. The
interaction is very strong, as shown by competition analy-
sis. This high affinity is in accordance with a previous in
vitro study, in which the NFI consensus binding motif was
determined by PCR-mediated random site selection [20].
We also observed an electrophoretic mobility shift using
extracts from cells not transfected with NFI-A expression
plasmids, probably caused by expression of endogenous
NFI proteins. The respective bands were much weaker
when NFI-A was overexpressed, either due to a limiting
input or due to a down-regulation of endogenous NFI-A
by forced NFI-A expression.
ChIP analysis confirmed that the brain-specific isoform of
NFI-A (NFI-A bs) binds to the regulatory region of the
mouse L1 gene in vivo as well. By contrast, we did not
observe reproducible binding of the ubiquitous NFI-A iso-
form (NFI-A st) to this genomic region in vivo, although
the in vitro interaction of NFI-A st with the full binding site
in L1 was at least as strong as the one of NFI-A bs. This dif-
ference might be caused by the different binding reaction
conditions in the two assays. Alternatively, post-transla-
tional modifications could be a reason for the different
behavior of NFI-A st and NFI-A bs in the two assays, in
particular phosphorylation, which has been implied in
regulating NFI activity by several studies [21-23]. Whereas
for EMSA, extracts from CHO cells were used, ChIP was
performed using N2A cells. It is thus tempting to speculate
that phosphorylation of crucial amino acid residues dif-BMC Molecular Biology 2009, 10:107 http://www.biomedcentral.com/1471-2199/10/107
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In vitro binding of NFI-A to its full binding site in the mouse L1 gene is confirmed by supershift and competition assays Figure 4
In vitro binding of NFI-A to its full binding site in the mouse L1 gene is confirmed by supershift and competition 
assays. EMSAs were performed with 32P-labeled oligonucleotides indicated above the autoradiograms (for a description, see 
Fig. 3). In both images (A-B), only the upper and lower parts of the respective autoradiogram are shown, the middle sections, 
which did not exhibit any signals, were cut out for reasons of space. A, Supershift experiment. NFI-A st "+": oligonucleotides 
were incubated with extracts from CHO cells transfected with pCHNFI-A (NFI-A st); NFI-A st "-": oligonucleotides were not 
pre-incubated with cell extracts (negative control). Where indicated, anti-HA antibody was added. Arrow a points at anti-HA-
antibody/NFI-A/DNA super-shifted complexes, while arrow b indicates NFI-A/DNA complexes. B, Competition analysis with 
the radioactively labeled NFI binding site from the mouse L1 gene regulatory region (L) and various unlabeled competitor oli-
gonucleotides (N, Nc, L, Lc; see Fig. 3 for a description). The 32P-labeled L oligonucleotide was incubated with extracts from 
CHO cells transfected with pCHNFI-A (NFI-A st) in the presence of different molar excesses of the unlabeled competitor oli-
gonucleotides as indicated above the autoradiogram. A "-" indicates that oligonucleotides were not pre-incubated with cell 
extracts (negative control). The arrow points at the main band representing NFI-A-DNA complexes.BMC Molecular Biology 2009, 10:107 http://www.biomedcentral.com/1471-2199/10/107
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NFI-A binds to the L1 gene in vivo Figure 5
NFI-A binds to the L1 gene in vivo. A, ChIP analysis of N2A cells expressing Myc-NFI-A. L1, NFI-A-DNA complexes in the 
region of the L1 gene containing the NFI full binding site were assayed by PCR using primers indicated in Fig. 1A. Lanes: NFI-A 
bs, precipitation from Myc-NFI-A bs-transfected cells; NFI-A st, precipitation from Myc-NFI-A st-transfected cells; mock, precip-
itation from mock-transfected cells; pos, positive control (mouse genomic DNA as PCR template); water, water control (with-
out PCR template). Chst8 and Chst11, To further confirm the specificity of ChIP analysis, ChIP samples were analyzed by PCR 
using primers amplifying parts of the mouse Chst8 and Chst11 genes, respectively. Note the absence of PCR signals for Chst8 
and Chst11 in the ChIP sample lanes. B, Expression of Myc-tagged NFI-A isoforms in N2A cells. N2A cells were transfected 
with 4.8 μg of NFI-A cDNA expression vectors to express Myc-NFI-A st or Myc-NFI-A bs, respectively, or with 4.8 μg pCMX 
plasmid ("mock"). 48 h after transfection, cell were lysed and whole cell extracts were analyzed on a 10% SDS-PAGE gel, trans-
ferred to nitrocellulose membrane, and probed with anti-Myc antibody for detection of recombinant Myc-NFI-A and with anti-
GAPDH antibody to check for loading of comparable protein amounts.BMC Molecular Biology 2009, 10:107 http://www.biomedcentral.com/1471-2199/10/107
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fers between NFI-A bs and NFI-A st in N2A cells, causing a
different affinity to the L1 gene regulatory region. Differ-
ences in protein phosphorylation or other modifications
might also explain why the apparent molecular weights of
NFI-A bs and NFI-A st differed slightly more than one
would expect from their amino acid composition. Finally,
it should be noted that eight half binding sites for NFI
proteins can be found in the 2400 bp immediately
upstream of the full site. NFI-A binds to such pentanucle-
otide sequences with a reduced affinity [20].
In order to understand how binding of NFI-A to the L1
regulatory region influences L1 expression, we performed
reporter gene assays in mouse neuroblastoma (N2A) cells.
NFI-A bs caused a reduction in L1 gene activity to approx.
30% of control level. In this context, it is noteworthy that
only the brain-specific isoform significantly interacted
with the endogenous L1 gene regulatory region. Moreo-
ver, we could nearly abolish repression of L1 transcription
by NFI-A bs by deleting NFI-A's transregulatory domain.
To our knowledge, these results are the first experimental
evidence for a specific role of NFI-A bs in the regulation of
a neuronal gene.
How could NFI-A activity at the L1 gene regulatory region
be regulated in a physiological context? Several studies
suggest that NFI activity is modulated by NFI phosphor-
ylation [21-23]. In our case, NFI-A could be inactivated by
phosphorylation, leading to enhanced L1 expression.
However, there is no direct evidence that phosphorylation
affects NFI activity.
Interactions with other site-specific transcription factors
might also regulate transactivation/transrepression by
NFI-A. NFI proteins physically interact with TTF-1 [24],
Oct-1 [25], ski [26], and CBP [27]. Binding of NFI-A to
such factors could alter its inhibitory influence on L1 tran-
scription initiation. Remarkably, the HPD element, which
NFI-A represses mouse L1 gene expression Figure 6
NFI-A represses mouse L1 gene expression. Results of luciferase-based reporter gene assays in N2A cells transfected 
with L1-11. The L1 reporter plasmid L1-11 contains 2943 bp upstream of exon 1 of the mouse L1 gene, exon 1, intron 1, exon 
2 with the luciferase cDNA inserted to replace the L1 start codon by the luciferase start codon, intron 2 including the neural 
restrictive silencer element, exon 3, intron 3 and exon 4. beta Gal: coexpression of beta-galactosidase (negative control) (n = 
98); NFI-A bs: coexpression of NFI-A bs (n = 91); NFI-A bs del: coexpression of NFI-A bs del (n = 35). For titration of beta Gal 
with NFI-A bs, the beta Gal expression plasmid was gradually replaced with the NFI-A bs expression plasmid at the ratios indi-
cated below, leaving the total amount of transfected DNA constant. "1", bs:Gal = 1:59 (n = 28); "2", bs:Gal = 1:11 (n = 35); "3", 
bs:Gal = 1:5 (n = 49); "4", bs:Gal = 1:2 (n = 21); "5", bs:Gal = 1:1 (n = 49); "6", bs:Gal = 2:1 (n = 21). Data were acquired from 
3 (bs:Gal = 1:2) to 9 (beta Gal, NFI-A bs) independent experiments. For normalization, luciferase activity was divided by the flu-
orescence of coexpressed EGFP. The relative luciferase activity of the beta Gal-transfected samples was set to 1. **, p < 0.01 
vs. beta Gal; ***, p < 0.001 vs. beta Gal; §§§, p < 0.001 vs. NFI-A bs (two-tailed, unpaired t-test).BMC Molecular Biology 2009, 10:107 http://www.biomedcentral.com/1471-2199/10/107
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is responsible for stimulation of L1 expression by Pax-6, is
located in the same part of the L1 gene as the full NFI
binding site identified in our study [6]. In addition, bind-
ing of the homeodomain proteins Barx-2 [6] and Hoxa-1
[5] to the L1 gene is also mediated by the HPD element.
This might implicate a functional interaction between NFI
transcription factors and Pax-6, Barx-2, or Hoxa-1 in regu-
lating L1 expression.
Conclusions
In summary, our data suggest that NFI-A is a repressor of
mouse L1 gene activity. A role for NFI-A in regulating L1
expression during development is plausible, as expression
of both genes starts around embryonic day 9 in the devel-
oping nervous system of the mouse [3,11]. In addition,
Kallunki et al. [3] have proposed a second silencer ele-
ment in the first intron of the L1 gene that functions
together with the NRSE to regulate L1 expression. NFI-A,
binding tightly to its recognition motifs in this intron and
repressing L1 expression, could be part of the proposed
silencer. It may prevent L1 expression at inappropriate
stages or cell types, like glia of the central nervous system,
consistent with the recently demonstrated importance of
NFI-A for glial cell differentiation [28-31]. As both L1 and
NFI-A are crucial for brain development in humans
[1,32], further investigations on regulation of L1 expres-
sion by NFI-A, for instance cell type-specific analyses of
NFI-A deficient mice during development, are likely to
significantly extend our knowledge of human brain for-
mation.
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